Results 131 to 140 of about 5,299 (208)

Theratyping as a tool to guide clinical decision-making in patients with suspected cystic fibrosis and variants currently ineligible for CFTR modulator therapy. [PDF]

Respir Med
Gannon RM, Wright BA, Bettis BA, Teresi ME, Fischer AJ, Weiner RL, Peña T, Hornick DB, Thornell IM, Rehman T, Pezzulo AA.   +10 more
europepmc   +1 more source

Changes in Sleep in Children and Adults with Cystic Fibrosis and Primary Ciliary Dyskinesia over Time and after CFTR Modulator Therapy. [PDF]

J Clin Med, 2023
Cohen-Cymberknoh M, Lehavi M, Gileles-Hillel A, Atia O, Breuer O, Reiter J.   +5 more
europepmc   +1 more source

Respiratory Muscle Function in Children and Adolescents with Cystic Fibrosis in the Era of CFTR Modulator Therapies. [PDF]

Children (Basel)
García-Pérez-de-Sevilla G, Blanco Velasco Á, Yvert T, Sanz-Santiago V, Tirado AM, López Neyra A, de Manuel C, Ruiz Valbuena M, Pérez-Ruiz M.   +8 more
europepmc   +1 more source

Antisense oligonucleotide targeting the E3 ligase RFFL potentiates CFTR modulator efficacy in CF primary bronchial epithelial cells. [PDF]

Mol Ther Nucleic Acids
Hinata D, Kai Y, Fukuda R, Kamada Y, Kasahara Y, Sasaki K, Yoshida T, Obika S, Inoue T, Okiyoneda T.   +9 more
europepmc   +1 more source

Clinical pharmacology of CFTR modulators

With the development of cystic fibrosis transmembrane receptor (CFTR) modulating drugs, the landscape in cystic fibrosis (CF) care has changed dramatically. These drugs enable the treatment of the underlying cause of the disease. Although CFTR modulators show an impressive clincal effect at group level in people with CF (pwCF) with specific mutations ...
Meer - van de Grint, Renske van der, Heijerman, H.G.M., Wilms, E.B.   +2 more
openaire   +1 more source

CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. [PDF]

Nat Commun
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK.   +16 more
europepmc   +1 more source

Height Velocity in Pediatric Cystic Fibrosis Under Triple CFTR Modulator Therapy: A Real-Life Monocentric Experience. [PDF]

J Clin Med
Boni A, d'Aniello F, Ubertini G, Cappa M, Ciciriello F, Majo F, Cristiani L, Alghisi F, Montemitro E, Bella S, De Marchis M, Cutrera R, Fiocchi AG.   +12 more
europepmc   +1 more source

Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: a cross-sectional analysis. [PDF]

Am J Clin Nutr
Gonzalez Ramirez LA, Suppakitjanusant P, Burley TM, Zaveri S, Stecenko AA, Hunt WR, Harris RA, Stallings VA, Ivie EA, Driggers C, Binongo JN, Ziegler TR, Alvarez JA.   +12 more
europepmc   +1 more source

Building Lay Society Knowledge and Education for Health Technology Assessment and Policy Engagement: Case of CFTR Modulator Access in Brazil. [PDF]

Healthcare (Basel)
de Oliveira VSB, Amaral MB, Camargo M, Lopes-Pacheco M.   +3 more
europepmc   +1 more source

Personalised CFTR Modulator Treatment Initiation and Monitoring in CF-Related Liver Disease: When Less Is More. [PDF]

Respirol Case Rep
Vekaria S, Kavanagh G, Mulrennan S.
europepmc   +1 more source